Liquidia price target raised to $25 from $22 at BofA

BofA raised the firm’s price target on Liquidia (LQDA) to $25 from $22 and keeps a Buy rating on the shares. The company’s Yutrepia was approved as a 505b2 alternative to United Therapeutics’ (UTHR) Tyvaso, the analyst tells investors in a research note. The firm says the Yutrepia label is highly similar Tyvaso, given the 505b2 nature of the regulatory program. BofA finds Liquidia shares undervalued relative to the peak sales opportunity.